News - Hikma Pharmaceuticals PLC

In the section of our website you can find press releases and regulatory announcements as downloadable PDF files.

» Trading Statement
20-Jul-2008
London, 19 July 2008: Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK)(DIFX:HIK) today comments on trading in the six months to 30 June 2008.

In the first half of 2008, our Branded business performed ahead of our expectations, with strong sales growth boosted by the smooth integration of the acquisitions made in the second half of 2007. Our Injectables business also performed well, delivering strong sales growth for the period.
» Hikma Pharmaceuticals PLC is a Regional Partner to the World Economic Forum on the Middle East
20-May-2008
As part of its continuous efforts to enhance its leading position in MENA, and in line with its responsibilities as a multinational company, Hikma Pharmaceuticals PLC was an official regional partner to the World Economic Forum summit on the Middle East...
» Hikma Pharmaceuticals Granted Environmental Certification
20-May-2008
After intensive efforts from its CSR (Corporate Social Responsibility) and Engineering teams, Hikma Pharmaceuticals Co. Ltd. has been granted the ISO 14001:2004 certification (Environment related) on May 15, 2008...
» Hikma Pharmaceuticals Launches “Hikma Global Volunteering Day”
15-Apr-2008
As part of Hikma Pharmaceuticals’ commitment to fulfilling its Corporate Social Responsibility (CSR) and in its firm belief in actively translating its Founder’s ethical principles into serving its communities in all its locations, Hikma has launched an annual Hikma Volunteering Day across its locations. This initiative reflects Hikma values as related to its involvement in local communities on a global scale as well as giving back to the communities.
» Hikma presents 2007 Preliminary results
18-Mar-2008
LONDON, 18 March 2008 - Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK) (DIFX:HIK), the fast-growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of generic and in-licensed pharmaceutical products, across the Middle East and North Africa, the US and Europe, today reports its preliminary results for the year ended 31 December 2007.
» Hikma Founder Samih Darwazah Selected Entrepreneur of the Year
24-Feb-2008
Hikma Pharmaceuticals Founder and Chairman Mr. Samih Darwazah has been selected as the Entrepreneur of the Year for the Middle East...
» Inauguration of Hikma Pharma-Egypt
24-Feb-2008
During a reception held earlier this month, and attended by the Egyptian Minister of Trade and Industry Mr. Rashid Mohammad Al Rasid and the board directors of Hikma Pharmaceuticals PLC and several key figures in Egypt, Hikma Pharma has officially started its operation in the Egyptian market...
» Result of placing of new ordinary shares
17-Jan-2008
Hikma Pharmaceuticals PLC (“Hikma”) announces that, further to the announcement on 17 January 2008 (the “Announcement”), a total of 17 million new ordinary shares of 10 pence each in Hikma (the "Placing Shares") have been placed by Merrill Lynch International ("Merrill Lynch") and Citigroup Global Markets U.K. Equity Limited (“Citi”) at a price of 480 pence per Placing Share, raising gross proceeds of approximately £81.6 million (the “Placing”).
» Placing of up to 17 million new ordinary shares
17-Jan-2008
Hikma Pharmaceuticals PLC (“Hikma” or the “Company”) intends to place up to 17 million new Ordinary Shares, representing up to 9.9 per cent of Hikma’s issued ordinary share capital immediately prior to the Placing, with institutional and other investors (the “Placing Shares”).
» Update on trading and reporting timetable
17-Jan-2008
LONDON, 17 January 2008 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (DIFX: HIK), the multinational pharmaceuticals group, confirms that since the publication of its pre-close trading statement on 14 December 2007 there has been no change to its expectations for the 2007 financial year or its outlook for 2008.